Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Vifor Pharma can help your patients access and afford VELTASSA

VELTASSA is covered without restrictions for 83% of all U.S. lives.

VELTASSA is covered without restrictions for 83% of all U.S. lives.*

  • If a payor requires prior authorization, use our request form
74% of patients paid $10 or less for their monthly VELTASSA prescriptions.

~74 % of patients paid $10 or less for their monthly VELTASSA prescriptions.

Eligible commercially insured patients may pay as little as $0 for VELTASSA per month for up to 12 months.

Eligible commercially insured patients may pay as little as $0 for VELTASSA per month for up to 12 months.

  • Instant savings at the pharmacy
  • No co-pay card or print coupon required
  • No patient registration

*As of June 2022 and may be subject to change.

Source: Source Health Analytics PTD Dispensed Claims (May 2021–April 2022).

Program is for commercially insured patients. Patients enrolled in a government health insurance program such as Medicare Part D, Medicaid, TRICARE, or Veterans Health Administration are not eligible; this is not an exhaustive list of excluded government health plans. Patients may pay as low as $0 for up to 12 months; after that, renewal is required. The patient is responsible for applicable taxes. Annual maximum limits apply. Co-pay program is not insurance. No party may seek reimbursement for any part of the co-pay benefit received under the program. See full Terms and Conditions below.

$0 Co-pay Important Terms and Conditions

By participating in Vifor Pharma, Inc.’s $0 Co-pay Savings Program (“Co-pay Program”) for VELTASSA, the patient acknowledges that, at the time of usage, they meet the eligibility criteria and comply with the following terms and conditions.

The Co-pay Program is for commercially insured patients. Patients with prescription coverage through any type of federal or state government-funded program are not eligible (e.g., Medicare, Medicaid, TRICARE, Veterans Administration [VA], Mi Salud).

The patient may pay as low as $0 per month for up to a 12-month period, and afterward renewal is required. Annual maximum limits may apply. The Co-pay Program for VELTASSA is not insurance. Vifor Pharma, Inc. reserves the right to rescind, revoke, or amend this program without notice. The patient must use the Co-pay Program for a valid prescription of VELTASSA, and this cannot be combined with any other coupon, trial, savings card, free drug assistance, or other offer.

Patient must live in the United States (including the District of Columbia, Puerto Rico, and the U.S. Virgin Islands). If the patient is enrolled in Veltassa Konnect, patient is required to promptly inform Veltassa Konnect of any change in insurance status during the course of enrollment.

The patient and participating pharmacy are each obligated to inform the insurance plan of any benefit received under the Co-pay Program as required and may not participate if the Co-pay Program conflicts with the plan’s policy. No party may seek reimbursement for any part of the benefit received by patient under the Co-pay Program. The patient is responsible for applicable taxes. Limit one per person; offer is non-transferable and void where prohibited by law or restricted.

Signup email

Get important updates and information about VELTASSA

Support to help your patients start and stay on therapy

Next
SEE MORE

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

top

INDICATION & Important Safety Information

Important Safety Information

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

INDICATION

VELTASSA is indicated for the treatment of hyperkalemia.

Limitation of Use: VELTASSA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VELTASSA is contraindicated in patients with a history of a hypersensitivity reaction to VELTASSA or any of its components.

WARNINGS AND PRECAUTIONS

Worsening of Gastrointestinal Motility: Avoid use of VELTASSA in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because VELTASSA may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnecemia: VELTASSA binds to magnesium in the colon, which can lead to hypomagnecemia. In clinical studies, hypomagnecemia was reported as an adverse reaction in 5.3% of patients treated with VELTASSA. Approximately 9% of patients in clinical trials developed hypomagnecemia with a serum magnesium value <1.4 mg/dL. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions (incidence ≥2%) were constipation (7.2%), hypomagnecemia (5.3%), diarrhea (4.8%), nausea (2.3%), abdominal discomfort (2.0%) and flatulence (2.0%). Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with VELTASSA and included edema of the lips.